Digirad (DRAD) vs. Its Peers Financial Review
Digirad (NASDAQ: DRAD) is one of 78 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its competitors? We will compare Digirad to related companies based on the strength of its risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.
Valuation and Earnings
This table compares Digirad and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Digirad||$125.47 million||$14.30 million||-4.14|
|Digirad Competitors||$2.14 billion||$234.27 million||-30.90|
Digirad pays an annual dividend of $0.22 per share and has a dividend yield of 9.2%. Digirad pays out -37.9% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 26.2% of their earnings in the form of a dividend. Digirad is clearly a better dividend stock than its competitors, given its higher yield and lower payout ratio.
Institutional and Insider Ownership
53.1% of Digirad shares are held by institutional investors. Comparatively, 51.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 11.9% of Digirad shares are held by company insiders. Comparatively, 18.2% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and recommmendations for Digirad and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Digirad currently has a consensus target price of $6.00, suggesting a potential upside of 150.00%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.09%. Given Digirad’s stronger consensus rating and higher probable upside, equities analysts clearly believe Digirad is more favorable than its competitors.
Volatility & Risk
Digirad has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Digirad’s competitors have a beta of 1.23, indicating that their average share price is 23% more volatile than the S&P 500.
This table compares Digirad and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Digirad beats its competitors on 11 of the 15 factors compared.
Digirad Company Profile
Digirad Corporation provides healthcare solutions. The Company’s segments include Diagnostic Services, Mobile Healthcare, Diagnostic Imaging and Medical Device Sales and Services. Through Diagnostic Services, the Company offers an imaging services program as an alternative to purchasing equipment or outsourcing the procedures to another physician or imaging center. Through Mobile Healthcare segment, the Company provides contract sales services and diagnostic imaging services. Through Diagnostic Imaging segment, the Company sells its internally developed solid-state gamma camera imaging systems and camera maintenance contracts. Through Medical Device Sales and Services segment, the Company provides contract sales services, as well as warranty and post-warranty services, under contract with Philips Healthcare within a defined region in the upper Midwest region of the United States.
Receive News & Ratings for Digirad Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad Co. and related companies with MarketBeat.com's FREE daily email newsletter.